IgG receptor FcRn large subunit p51 (Protein)

Description: A protein in the knowledge graph

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View IgG receptor FcRn large subunit p51 's neighborhood in the knowledge graph.

Submit

Knowledge Graph Assertions

Source	Relation	Target	Evidence
(2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-{2-[(3R)-3-[(2S)-2-[(2S)-2-{2-[(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methyl-3-sulfanylbutanamido]-3-hydroxybutanamido]acetamido}-3-(1H-imidazol-5-yl)propanamido]-3-phenylpropanamido]-2-oxoazepan-1-yl]-N-methylacetamido}-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanoic acid Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	IgG receptor FcRn large subunit p51 Protein (Entity type)	Kd
(S)-2-(2-(2-((S)-1-((3S,11S,14S,20S,23S,32S,35S,41aS)-20-((1H-imidazol-4-yl)methyl)-3-((S)-4-amino-1-(2-((S)-2-carbamoylpyrrolidin-1-yl)-2-oxoethylamino)-1,4-dioxobutan-2-ylcarbamoyl)-23-benzyl-35-(4-hydroxybenzyl)-14-((R)-1-hydroxyethyl)-32-isobutyl-28,31-dimethyl-1,9,12,15,18,21,24,27,30,33,36,37-dodecaoxotetracontahydro-1H-pyrrolo[1,2-z][1,4,7,10,13,16,19,22,26,29,35]undecaazacyclononatriacontin-11-ylamino)-1-oxo-3-phenylpropan-2-ylamino)-2-oxoethylthio)acetamido)-N1-((S)-1-((S)-1-((3S,11S,14S,20S,23S,32S,35S,41aS)-20-((1H-imidazol-4-yl)methyl)-3-((S)-4-amino-1-(2-((S)-2-carbamoylpyrrolidin-1-yl)-2-oxoethylamino)-1,4-dioxobutan-2-ylcarbamoyl)-23-benzyl-35-(4-hydroxybenzyl)-14-((R)-1-hydroxyethyl)-32-isobutyl-28,31-dimethyl-1,9,12,15,18,21,24,27,30,33,36,37-dodecaoxotetracontahydro-1H-pyrrolo[1,2-z][1,4,7,10,13,16,19,22,26,29,35]undecaazacyclononatriacontin-11-ylamino)-1-oxo-3-phenylpropan-2-ylamino)-5-guanidino-1-oxopentan-2-yl)pentanediamide Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	IgG receptor FcRn large subunit p51 Protein (Entity type)	IC50
N1-((S)-1-((S)-1-((3S,11S,14S,20S,23S,32S,35S,41aS)-20-((1H-imidazol-4-yl)methyl)-23-benzyl-3-carbamoyl-35-(4-hydroxybenzyl)-14-((R)-1-hydroxyethyl)-32-isobutyl-28,31-dimethyl-1,9,12,15,18,21,24,27,30,33,36,37-dodecaoxotetracontahydro-1H-pyrrolo[1,2-z][1,4,7,10,13,16,19,22,26,29,35]undecaazacyclononatriacontin-11-ylamino)-1-oxo-3-phenylpropan-2-ylamino)-5-guanidino-1-oxopentan-2-yl)-N4-(2-((2-((S)-1-((S)-1-((3S,11S,14S,20S,23S,32S,35S,41aS)-20-((1H-imidazol-4-yl)methyl)-23-benzyl-3-carbamoyl-35-(4-hydroxybenzyl)-14-((R)-1-hydroxyethyl)-32-isobutyl-28,31-dimethyl-1,9,12,15,18,21,24,27,30,33,36,37-dodecaoxotetracontahydro-1H-pyrrolo[1,2-z][1,4,7,10,13,16,19,22,26,29,35]undecaazacyclononatriacontin-11-ylamino)-1-oxo-3-phenylpropan-2-ylamino)-5-guanidino-1-oxopentan-2-ylamino)-2-oxoethyl)(methyl)amino)ethyl)succinamide Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	IgG receptor FcRn large subunit p51 Protein (Entity type)	IC50
(R,S,S,3R,3'R,8R,8'R,11S,11'S,17S,17'S,20S,20'S,29S,29'S,32S,32'S,38aS,38a'S)-N,N'-(2,2'-(2,2'-azanediylbis(ethane-2,1-diyl)bis(azanediyl))bis(2-oxoethane-2,1-diyl))bis(17-((1H-imidazol-4-yl)methyl)-8-((S)-2-((S)-2-amino-5-guanidinopentanamido)-3-phenylpropanamido)-20-benzyl-32-(4-hydroxybenzyl)-11-((R)-1-hydroxyethyl)-29-isobutyl-7,7,25,28-tetramethyl-1,9,12,15,18,21,24,27,30,33,34-undecaoxohexatriacontahydropyrrolo[2,1-g][1,2,5,8,12,15,18,21,24,27,30,33]dithiadecaazacyclohexatriacontine-3-carboxamide) Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	IgG receptor FcRn large subunit p51 Protein (Entity type)	IC50
IgG receptor FcRn large subunit p51 Protein (Entity type)	Has isoform Knowledge Graph Relation (Entity type)	UNIPROTKB.ISOFORM:P55899-1 CUI Isoform (Entity type)
N-[(1S)-1-{[(1S)-1-{[(5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-18-carbamoyl-8-[(4-hydroxyphenyl)methyl]-32-(1H-imidazol-4-ylmethyl)-4,22,22,25,26-pentamethyl-5-(2-methylpropyl)-3,6,9,10,16,24,27,30,33,36,42-undecaoxo-20,21-dithia-1,4,7,11,17,25,28,31,34,37-decaazatricyclo[36.3.1.0^{11,15}]dotetracontan-23-yl]carbamoyl}-2-phenylethyl]carbamoyl}-4-carbamimidamidobutyl]-N'-{2-[({[(1S)-1-{[(1S)-1-{[(5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-18-carbamoyl-8-[(4-hydroxyphenyl)methyl]-32-(1H-imidazol-4-ylmethyl)-4,22,22,25,26-pentamethyl-5-(2-methylpropyl)-3,6,9,10,16,24,27,30,33,36,42-undecaoxo-20,21-dithia-1,4,7,11,17,25,28,31,34,37-decaazatricyclo[36.3.1.0^{11,15}]dotetracontan-23-yl]carbamoyl}-2-phenylethyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}methyl)(methyl)amino]ethyl}butanediamide Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	IgG receptor FcRn large subunit p51 Protein (Entity type)	IC50
(5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-23-[(2S)-2-[(2S)-5-carbamimidamido-2-acetamidopentanamido]-3-phenylpropanamido]-8-[(4-hydroxyphenyl)methyl]-32-(1H-imidazol-4-ylmethyl)-4,22,22,25,26-pentamethyl-5-(2-methylpropyl)-3,6,9,10,16,24,27,30,33,36,42-undecaoxo-20,21-dithia-1,4,7,11,17,25,28,31,34,37-decaazatricyclo[36.3.1.0^{11,15}]dotetracontane-18-carboxamide Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	IgG receptor FcRn large subunit p51 Protein (Entity type)	Kd
2-[2-({3-[3-(3-{3-[3-({[(1S)-1-{[(1S)-1-{[(1S)-1-{[(3S,11S,14S,20S,23S,32S,35S,41aS)-23-benzyl-3-{[(1S)-2-carbamoyl-1-({2-[(2S)-2-carbamoylpyrrolidin-1-yl]-2-oxoethyl}carbamoyl)ethyl]carbamoyl}-14-[(1R)-1-hydroxyethyl]-35-[(4-hydroxyphenyl)methyl]-20-(1H-imidazol-4-ylmethyl)-28,31-dimethyl-32-(2-methylpropyl)-1,9,12,15,18,21,24,27,30,33,36,37-dodecaoxo-tetracontahydro-1H-pyrrolo[1,2-z]1,4,7,10,13,16,19,22,26,29,35-undecaazacyclononatriacontan-11-yl]carbamoyl}-2-phenylethyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}-3-carbamoylpropyl]carbamoyl}sulfanyl)propanamido]propanamido}propanamido)propanamido]propyl}[3-({2-[3-(3-{3-[({[(1S)-1-{[(3S,11S,14S,20S,23S,32S,35S,41aS)-23-benzyl-3-{[(1S)-2-carbamoyl-1-({2-[(2S)-2-carbamoylpyrrolidin-1-yl]-2-oxoethyl}carbamoyl)ethyl]carbamoyl}-14-[(1R)-1-hydroxyethyl]-35-[(4-hydroxyphenyl)methyl]-20-(1H-imidazol-4-ylmethyl)-28,31-dimethyl-32-(2-methylpropyl)-1,9,12,15,18,21,24,27,30,33,36,37-dodecaoxo-tetracontahydro-1H-pyrrolo[1,2-z]1,4,7,10,13,16,19,22,26,29,35-undecaazacyclononatriacontan-11-yl]carbamoyl}-2-phenylethyl]carbamoyl}methyl)sulfanyl]propanamido}propanamido)propanamido]ethyl}amino)propyl]amino)acetamido]acetic acid Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	IgG receptor FcRn large subunit p51 Protein (Entity type)	IC50
(3R,8R,11S,17S,20S,29S,32S,38aS)-8-[(2S)-2-[(2S)-2-{2-[({[(1S)-1-{[(1S)-1-{[(3R,8R,11S,17S,20S,29S,32S,38aS)-20-benzyl-3-carbamoyl-11-[(1R)-1-hydroxyethyl]-32-[(4-hydroxyphenyl)methyl]-17-(1H-imidazol-4-ylmethyl)-7,7,25,28-tetramethyl-29-(2-methylpropyl)-1,9,12,15,18,21,24,27,30,33,34-undecaoxo-hexatriacontahydropyrrolo[2,1-g]1,2-dithia-5,8,12,15,18,21,24,27,30,33-decaazacyclohexatriacontan-8-yl]carbamoyl}-2-phenylethyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}methyl)(methyl)amino]acetamido}-5-carbamimidamidopentanamido]-3-phenylpropanamido]-20-benzyl-11-[(1R)-1-hydroxyethyl]-32-[(4-hydroxyphenyl)methyl]-17-(1H-imidazol-4-ylmethyl)-7,7,25,28-tetramethyl-29-(2-methylpropyl)-1,9,12,15,18,21,24,27,30,33,34-undecaoxo-hexatriacontahydropyrrolo[2,1-g]1,2-dithia-5,8,12,15,18,21,24,27,30,33-decaazacyclohexatriacontane-3-carboxamide Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	IgG receptor FcRn large subunit p51 Protein (Entity type)	IC50
(5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-23-[(2S)-2-[(2S)-5-carbamimidamido-2-acetamidopentanamido]-3-phenylpropanamido]-26-[(1R)-1-hydroxyethyl]-8-[(4-hydroxyphenyl)methyl]-32-(1H-imidazol-4-ylmethyl)-4,22,22-trimethyl-5-(2-methylpropyl)-3,6,9,10,16,24,27,30,33,36,42-undecaoxo-20,21-dithia-1,4,7,11,17,25,28,31,34,37-decaazatricyclo[36.3.1.0^{11,15}]dotetracontane-18-carboxamide Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	IgG receptor FcRn large subunit p51 Protein (Entity type)	Kd

(2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-{2-[(3R)-3-[(2S)-2-[(2S)-2-{2-[(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-phenylpropanamido]-3-methyl-3-sulfanylbutanamido]-3-hydroxybutanamido]acetamido}-3-(1H-imidazol-5-yl)propanamido]-3-phenylpropanamido]-2-oxoazepan-1-yl]-N-methylacetamido}-4-methylpentanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanoic acid
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
IgG receptor FcRn large subunit p51
Protein (Entity type)
Kd

(S)-2-(2-(2-((S)-1-((3S,11S,14S,20S,23S,32S,35S,41aS)-20-((1H-imidazol-4-yl)methyl)-3-((S)-4-amino-1-(2-((S)-2-carbamoylpyrrolidin-1-yl)-2-oxoethylamino)-1,4-dioxobutan-2-ylcarbamoyl)-23-benzyl-35-(4-hydroxybenzyl)-14-((R)-1-hydroxyethyl)-32-isobutyl-28,31-dimethyl-1,9,12,15,18,21,24,27,30,33,36,37-dodecaoxotetracontahydro-1H-pyrrolo[1,2-z][1,4,7,10,13,16,19,22,26,29,35]undecaazacyclononatriacontin-11-ylamino)-1-oxo-3-phenylpropan-2-ylamino)-2-oxoethylthio)acetamido)-N1-((S)-1-((S)-1-((3S,11S,14S,20S,23S,32S,35S,41aS)-20-((1H-imidazol-4-yl)methyl)-3-((S)-4-amino-1-(2-((S)-2-carbamoylpyrrolidin-1-yl)-2-oxoethylamino)-1,4-dioxobutan-2-ylcarbamoyl)-23-benzyl-35-(4-hydroxybenzyl)-14-((R)-1-hydroxyethyl)-32-isobutyl-28,31-dimethyl-1,9,12,15,18,21,24,27,30,33,36,37-dodecaoxotetracontahydro-1H-pyrrolo[1,2-z][1,4,7,10,13,16,19,22,26,29,35]undecaazacyclononatriacontin-11-ylamino)-1-oxo-3-phenylpropan-2-ylamino)-5-guanidino-1-oxopentan-2-yl)pentanediamide
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
IgG receptor FcRn large subunit p51
Protein (Entity type)
IC50

N1-((S)-1-((S)-1-((3S,11S,14S,20S,23S,32S,35S,41aS)-20-((1H-imidazol-4-yl)methyl)-23-benzyl-3-carbamoyl-35-(4-hydroxybenzyl)-14-((R)-1-hydroxyethyl)-32-isobutyl-28,31-dimethyl-1,9,12,15,18,21,24,27,30,33,36,37-dodecaoxotetracontahydro-1H-pyrrolo[1,2-z][1,4,7,10,13,16,19,22,26,29,35]undecaazacyclononatriacontin-11-ylamino)-1-oxo-3-phenylpropan-2-ylamino)-5-guanidino-1-oxopentan-2-yl)-N4-(2-((2-((S)-1-((S)-1-((3S,11S,14S,20S,23S,32S,35S,41aS)-20-((1H-imidazol-4-yl)methyl)-23-benzyl-3-carbamoyl-35-(4-hydroxybenzyl)-14-((R)-1-hydroxyethyl)-32-isobutyl-28,31-dimethyl-1,9,12,15,18,21,24,27,30,33,36,37-dodecaoxotetracontahydro-1H-pyrrolo[1,2-z][1,4,7,10,13,16,19,22,26,29,35]undecaazacyclononatriacontin-11-ylamino)-1-oxo-3-phenylpropan-2-ylamino)-5-guanidino-1-oxopentan-2-ylamino)-2-oxoethyl)(methyl)amino)ethyl)succinamide
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
IgG receptor FcRn large subunit p51
Protein (Entity type)
IC50

(R,S,S,3R,3'R,8R,8'R,11S,11'S,17S,17'S,20S,20'S,29S,29'S,32S,32'S,38aS,38a'S)-N,N'-(2,2'-(2,2'-azanediylbis(ethane-2,1-diyl)bis(azanediyl))bis(2-oxoethane-2,1-diyl))bis(17-((1H-imidazol-4-yl)methyl)-8-((S)-2-((S)-2-amino-5-guanidinopentanamido)-3-phenylpropanamido)-20-benzyl-32-(4-hydroxybenzyl)-11-((R)-1-hydroxyethyl)-29-isobutyl-7,7,25,28-tetramethyl-1,9,12,15,18,21,24,27,30,33,34-undecaoxohexatriacontahydropyrrolo[2,1-g][1,2,5,8,12,15,18,21,24,27,30,33]dithiadecaazacyclohexatriacontine-3-carboxamide)
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
IgG receptor FcRn large subunit p51
Protein (Entity type)
IC50

IgG receptor FcRn large subunit p51
Protein (Entity type)
Has isoform
Knowledge Graph Relation (Entity type)
UNIPROTKB.ISOFORM:P55899-1 CUI
Isoform (Entity type)

N-[(1S)-1-{[(1S)-1-{[(5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-18-carbamoyl-8-[(4-hydroxyphenyl)methyl]-32-(1H-imidazol-4-ylmethyl)-4,22,22,25,26-pentamethyl-5-(2-methylpropyl)-3,6,9,10,16,24,27,30,33,36,42-undecaoxo-20,21-dithia-1,4,7,11,17,25,28,31,34,37-decaazatricyclo[36.3.1.0^{11,15}]dotetracontan-23-yl]carbamoyl}-2-phenylethyl]carbamoyl}-4-carbamimidamidobutyl]-N'-{2-[({[(1S)-1-{[(1S)-1-{[(5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-18-carbamoyl-8-[(4-hydroxyphenyl)methyl]-32-(1H-imidazol-4-ylmethyl)-4,22,22,25,26-pentamethyl-5-(2-methylpropyl)-3,6,9,10,16,24,27,30,33,36,42-undecaoxo-20,21-dithia-1,4,7,11,17,25,28,31,34,37-decaazatricyclo[36.3.1.0^{11,15}]dotetracontan-23-yl]carbamoyl}-2-phenylethyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}methyl)(methyl)amino]ethyl}butanediamide
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
IgG receptor FcRn large subunit p51
Protein (Entity type)
IC50

(5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-23-[(2S)-2-[(2S)-5-carbamimidamido-2-acetamidopentanamido]-3-phenylpropanamido]-8-[(4-hydroxyphenyl)methyl]-32-(1H-imidazol-4-ylmethyl)-4,22,22,25,26-pentamethyl-5-(2-methylpropyl)-3,6,9,10,16,24,27,30,33,36,42-undecaoxo-20,21-dithia-1,4,7,11,17,25,28,31,34,37-decaazatricyclo[36.3.1.0^{11,15}]dotetracontane-18-carboxamide
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
IgG receptor FcRn large subunit p51
Protein (Entity type)
Kd

2-[2-({3-[3-(3-{3-[3-({[(1S)-1-{[(1S)-1-{[(1S)-1-{[(3S,11S,14S,20S,23S,32S,35S,41aS)-23-benzyl-3-{[(1S)-2-carbamoyl-1-({2-[(2S)-2-carbamoylpyrrolidin-1-yl]-2-oxoethyl}carbamoyl)ethyl]carbamoyl}-14-[(1R)-1-hydroxyethyl]-35-[(4-hydroxyphenyl)methyl]-20-(1H-imidazol-4-ylmethyl)-28,31-dimethyl-32-(2-methylpropyl)-1,9,12,15,18,21,24,27,30,33,36,37-dodecaoxo-tetracontahydro-1H-pyrrolo[1,2-z]1,4,7,10,13,16,19,22,26,29,35-undecaazacyclononatriacontan-11-yl]carbamoyl}-2-phenylethyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}-3-carbamoylpropyl]carbamoyl}sulfanyl)propanamido]propanamido}propanamido)propanamido]propyl}[3-({2-[3-(3-{3-[({[(1S)-1-{[(3S,11S,14S,20S,23S,32S,35S,41aS)-23-benzyl-3-{[(1S)-2-carbamoyl-1-({2-[(2S)-2-carbamoylpyrrolidin-1-yl]-2-oxoethyl}carbamoyl)ethyl]carbamoyl}-14-[(1R)-1-hydroxyethyl]-35-[(4-hydroxyphenyl)methyl]-20-(1H-imidazol-4-ylmethyl)-28,31-dimethyl-32-(2-methylpropyl)-1,9,12,15,18,21,24,27,30,33,36,37-dodecaoxo-tetracontahydro-1H-pyrrolo[1,2-z]1,4,7,10,13,16,19,22,26,29,35-undecaazacyclononatriacontan-11-yl]carbamoyl}-2-phenylethyl]carbamoyl}methyl)sulfanyl]propanamido}propanamido)propanamido]ethyl}amino)propyl]amino)acetamido]acetic acid
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
IgG receptor FcRn large subunit p51
Protein (Entity type)
IC50

(3R,8R,11S,17S,20S,29S,32S,38aS)-8-[(2S)-2-[(2S)-2-{2-[({[(1S)-1-{[(1S)-1-{[(3R,8R,11S,17S,20S,29S,32S,38aS)-20-benzyl-3-carbamoyl-11-[(1R)-1-hydroxyethyl]-32-[(4-hydroxyphenyl)methyl]-17-(1H-imidazol-4-ylmethyl)-7,7,25,28-tetramethyl-29-(2-methylpropyl)-1,9,12,15,18,21,24,27,30,33,34-undecaoxo-hexatriacontahydropyrrolo[2,1-g]1,2-dithia-5,8,12,15,18,21,24,27,30,33-decaazacyclohexatriacontan-8-yl]carbamoyl}-2-phenylethyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}methyl)(methyl)amino]acetamido}-5-carbamimidamidopentanamido]-3-phenylpropanamido]-20-benzyl-11-[(1R)-1-hydroxyethyl]-32-[(4-hydroxyphenyl)methyl]-17-(1H-imidazol-4-ylmethyl)-7,7,25,28-tetramethyl-29-(2-methylpropyl)-1,9,12,15,18,21,24,27,30,33,34-undecaoxo-hexatriacontahydropyrrolo[2,1-g]1,2-dithia-5,8,12,15,18,21,24,27,30,33-decaazacyclohexatriacontane-3-carboxamide
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
IgG receptor FcRn large subunit p51
Protein (Entity type)
IC50

(5S,8S,15S,18R,23R,26S,32S,35S,38S)-35-benzyl-23-[(2S)-2-[(2S)-5-carbamimidamido-2-acetamidopentanamido]-3-phenylpropanamido]-26-[(1R)-1-hydroxyethyl]-8-[(4-hydroxyphenyl)methyl]-32-(1H-imidazol-4-ylmethyl)-4,22,22-trimethyl-5-(2-methylpropyl)-3,6,9,10,16,24,27,30,33,36,42-undecaoxo-20,21-dithia-1,4,7,11,17,25,28,31,34,37-decaazatricyclo[36.3.1.0^{11,15}]dotetracontane-18-carboxamide
Compound (Entity type)
Bioactivity
Knowledge Graph Relation (Entity type)
IgG receptor FcRn large subunit p51
Protein (Entity type)
Kd

DISPLAY PER PAGE

Knowledge Graph Assertions

	Source	Relation	Target	Evidence
Loading results...

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2025

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.